PT Inquest is an online journal club. Hosted by Erik Meira and JW Matheson, the show looks at an article every week and discusses how they apply to current physical therapy practice.
A Closer Look at Egrifta, a Newly Approved Treatment for HIV-Associated Belly Fat Gain (Lipohypertrophy)
Manage episode 127184 series 2246
Player FM과 저희 커뮤니티의 TheBody.com: Podcast Central 콘텐츠는 모두 원 저작자에게 속하며 Player FM이 아닌 작가가 저작권을 갖습니다. 오디오는 해당 서버에서 직접 스트리밍 됩니다. 구독 버튼을 눌러 Player FM에서 업데이트 현황을 확인하세요. 혹은 다른 팟캐스트 앱에서 URL을 불러오세요.
On Nov. 10, Egrifta (tesamorelin) became the first drug approved in the U.S. to treat unusual fat gain, or lipohypertrophy, in people with HIV. In our latest episode of This Month in HIV, we talk with noted HIV researcher Daniel Berger, M.D., about how Egrifta works, who should take it, and what else we know to date about the treatment of lipohypertrophy.